MEDICINOVA REPORTS POSITIVE RESULTS FOR PHASE I OF MN-029

摘要

MediciNova,Inc.,San Diego,Calif.,a biopharmaceutical company that is publicly traded on the Nasdaq Global Market(Nasdaq:MNOV)and the Hercules Market of the Osaka Securities Exchange(Code Number:4875),has announced that it presented positive findings from a Phase I clinical study of MN-029,its novel vascular disrupting agent(VDA),at the 14th European Cancer Conference(ECCO 14)in Barcelona,Spain.